（文章来源：证券日报） 证券日报网讯晨光生物10月22日在互动平台回答投资者提问时表示，结合深交所信息披露的要求及公司 情况，公司在定期报告中披露每月末股东人数情况，敬请留意公司在指定信息披露媒体披露的定期报 告。 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—113 晨光生物科技集团股份有限公司 关于注销部分募集资金专户的公告 截至公告披露日，公司募集资金专户开立情况如下： | 2 | 中国银行股份有限公司曲 | 100835054447 | | 已销户 | | --- | --- | --- | --- | --- | | | 周支行 | | | | | 3 | 兴业银行股份有限公司石 | 572010100101566380 | | 已销户 | | | 家庄分行 | | | | | | 中国光大银行股份有限公 | 50520188000193885 | 天然植物综合提取一 | 已销户 | | 4 | 司邯郸分行 | | 体化项目（一期） | | | 5 | 中国农业银行股份有限公 | 50163401040001334 | | 已销户 | | | 司曲周县支行 | | | | | 6 | 沧州银行股份有限公司邯 | 6300120100000224700 | | 已销户 | | | 郸分行 | | | | | 7 | 中信银行股份有限公司海 | 8115801013600077553 | 红辣素精 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—112 晨光生物科技集团股份有限公司 关于子公司归还银行借款暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）对合并报表范围内子 公司银行借款担保情况因业务进展发生了变动，现公告如下： 一、对外担保基本情况及进展 1、结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，晨光生 物科技集团图木舒克有限公司（以下简称"图木舒克晨光"，系新疆晨光生物科 技股份有限公司全资子公司，穿透后为公司控股子公司）前期向上海浦东发展银 行股份有限公司喀什分行（以下简称："浦发银行"）提出 5,000 万元流动资金 借款申请。经过核查，浦发银行同意了图木舒克晨光的借款申请，担保方式为： 公司保证担保。 公司与浦发银行签署了《最高额保证合同》，被担保主债权本金余额不超过 伍仟万元；保证方式为：连带责任保证；保证范围为：主债权、利息、违约金、 损害赔偿金、手续费及其他为签订或履行本合同而发生的费用、以及债权人实现 担保权利和债权所产生 ...

Market Overview - In September 2025, the domestic retail sales (社零) totaled 4.20 trillion yuan, with a year-on-year growth of 3.0%, slightly below market expectations [6][4] - Cumulative retail sales from January to September 2025 reached 36.59 trillion yuan, reflecting a year-on-year increase of 4.5% [6] - Online retail channels continued to outperform the overall retail market, with physical goods online retail sales growing by 6.5% year-on-year [6] Apparel and Textile Industry - The textile and apparel retail sales in September 2025 showed marginal improvement, with a cumulative year-on-year growth of 3.1% from January to September [5] - The sports and entertainment goods segment experienced faster growth, with a cumulative year-on-year increase of 19.6% and a monthly growth of 11.9% in September [5] - Companies like 361 Degrees and Xtep International reported healthy growth in retail sales, with 361 Degrees leveraging high-quality products and rapid expansion of super stores [5][12] Cosmetics and Jewelry Sector - The cosmetics sector saw a year-on-year growth of 8.6% in September, with a month-on-month increase of 3.5 percentage points [6] - The gold and jewelry retail sales grew by 9.7% year-on-year, although demand was temporarily suppressed by rising gold prices [6][8] - The performance of brands like Lao Pu Gold during the "Double 11" shopping festival was exceptionally strong, achieving record sales [8][12] Export Performance - From January to September 2025, China's textile and apparel exports amounted to 106.48 billion USD and 115.21 billion USD respectively, with year-on-year growth rates of 2.1% and a decline of 2.5% [9][12] - Vietnam's textile and apparel exports showed a cumulative year-on-year growth of 8.77%, indicating a competitive edge in the region [9][12] Company-Specific Insights - Morning Light Bio (晨光生物) is expected to report a net profit of 278 million to 314 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 344.05% to 401.55% [13][15] - The company is positioned to benefit from the FDA's new policies promoting natural colorants, with the global natural colorant market projected to double from 2.1 billion USD to 4.2 billion USD [13][14] - Morning Light Bio's key products, such as chili red and lutein, are leading in the global market, enhancing its competitive position [13][15]

Investment Rating - The report assigns a "Buy-B" rating for the company, indicating a positive outlook for its stock performance in the near term [3][8]. Core Insights - The company is expected to benefit from the recent FDA policy changes that aim to phase out petroleum-based synthetic colorants, potentially doubling the global natural colorant market from $2.1 billion to $4.2 billion by 2026 [5][6]. - The company has reported a significant increase in net profit for the first three quarters of 2025, with an expected growth of 344.05% to 401.55% year-on-year, amounting to between 278 million to 314 million yuan [3][4]. - The company is positioned as a leading player in the global plant extract industry, with its main products, including capsicum red, capsicum oleoresin, and lutein, ranking first or among the top in the world [4]. Financial Performance - The company forecasts revenues of 7.125 billion yuan, 8.084 billion yuan, and 8.857 billion yuan for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 1.9%, 13.4%, and 9.6% [8][10]. - The projected net profit for the same years is expected to be 359 million yuan, 492 million yuan, and 585 million yuan, with year-on-year growth rates of 282.2%, 36.9%, and 18.9% [8][10]. - The earnings per share (EPS) are projected to be 0.74 yuan, 1.02 yuan, and 1.21 yuan for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 19.4, 14.1, and 11.9 [8][10].

Core Insights - A total of 133 A-share listed companies have released performance forecasts for the first three quarters of 2025, indicating a significant level of market activity [1] - Among these, 9 companies, including Xinda Co., Chujian New Materials, Yinglian Co., Shobead, Guangdong Mingzhu, Rongzhi Rixin, Shenghe Resources, Limin Co., and Chenguang Biological, are expected to see their net profits increase by over 400% year-on-year [1] Group 1 - 133 A-share listed companies have published performance forecasts for the first three quarters of 2025 [1] - 9 companies are projected to have net profit growth exceeding 400% year-on-year [1] - Guangdong Mingzhu's performance forecast announcement led to a significant stock price increase, with the stock closing at a 6-day, 3-board rise [1]

Core Insights - The market's focus on corporate performance has significantly increased with the ongoing disclosure of Q3 reports, with 46 institutions conducting 195 "buy" ratings covering 140 stocks as of October 17 [2][8] - Among the stocks rated, Zhongchong Co. and Xiaoshangpin City received the highest number of ratings, with 16 and 9 institutions respectively [2][3] - Zhongchong Co. reported a revenue of 3.86 billion yuan for the first three quarters, a year-on-year increase of 21.05%, and a net profit of 333 million yuan, up 18.21% [2] Company Performance - Zhongchong Co. has successfully entered the North American market through its WANPY brand on Chewy, the largest pet e-commerce platform in North America, indicating ongoing channel development [2] - Among the 140 stocks rated, 32 reported a year-on-year increase in net profit for the first three quarters, with Shijia Photon and Chenguang Biotech showing net profit growth exceeding 100% [8] - Shijia Photon achieved a net profit of 300 million yuan, a staggering increase of 727.74%, driven by the rapid growth of the data communication market due to AI development [8] - Chenguang Biotech's estimated net profit for the first three quarters ranges from 278 million to 314 million yuan, reflecting a year-on-year growth of 344.05% to 401.55% [8] Industry Trends - The pharmaceutical and biotechnology sectors are seeing a surge in positive news, with new regulations aimed at promoting biomedical innovation and improving medical quality [5][6] - The electronic industry is also favored by institutions, with AI technology driving new growth, particularly in high-bandwidth memory (HBM) demand, which is expected to grow by 70% globally by 2025 [6] - The average increase in stock prices for the 140 rated stocks this year is 39.56%, with 14 stocks experiencing gains exceeding 100%, highlighting strong market performance [9]

Core Insights - 31 companies listed on the ChiNext board have released their performance forecasts for the first three quarters, with 25 companies expecting profit increases, representing 80.65% of the total [1] - The overall proportion of companies with positive forecasts (including profit increases and profit forecasts) stands at 87.10%, with only 4 companies expecting profit declines [1] Performance Forecasts - Among the companies with positive forecasts, 11 are expected to see net profit growth exceeding 100%, while 6 companies anticipate growth between 50% and 100% [1] - ShuoBeide (300322) is projected to have the highest net profit growth at 1285.82%, followed by Chenguang Biological (300138) at 372.80% and Ice River Network (300533) at 207.09% [1] Market Performance - Stocks of companies expecting profit growth have seen an average increase of 98.75% this year, with notable performers including Zhenyu Technology (300953) up 243.48%, Jinli Yongchang (300748) up 129.80%, and Guangku Technology (300620) up 105.43% [1] - Recent performance over the last five days shows Chenguang Biological (300138) up 10.87%, Jinli Yongchang (300748) up 3.47%, and Chuanjin Nuo (300505) up 1.20% [1] Company Performance Table - A detailed table lists companies with their respective codes, expected net profit growth percentages, latest closing prices, year-to-date performance, and industry classifications [1][2]

Core Insights - 30 companies listed on the ChiNext board have released their performance forecasts for the first three quarters, with 24 companies expecting profit increases, representing 80.00% of the total [1] - The overall proportion of companies with positive forecasts is 86.67%, with 2 companies expecting to turn a profit and 4 companies forecasting profit declines [1] Performance Forecasts - Among the companies expecting profit increases, 10 companies anticipate a net profit growth exceeding 100%, while 6 companies expect growth between 50% and 100% [1] - ShuoBeide (300322) leads with a projected net profit growth of 1285.82%, followed by Chenguang Biotech (300138) at 372.80% and Ice River Network (300533) at 207.09% [1] Market Performance - Stocks with expected profit doubling have seen an average increase of 102.14% year-to-date, with notable performers including Zhenyu Technology (300953) up 256.27%, Jinli Permanent Magnet (300748) up 142.52%, and Ice River Network (300533) up 94.89% [1] - Recent performance over the last five days shows Jinli Permanent Magnet (300748) up 25.75%, Feirongda (300602) up 11.28%, and Chenguang Biotech (300138) up 8.31% [1] Company Performance Table - A detailed table lists companies with their respective codes, expected profit growth percentages, latest closing prices, year-to-date performance, and industry classifications [1][2]

Group 1: Semiconductor Industry - The largest domestic chip testing company, Weicai Technology, reported a consolidated revenue of 448.32 million yuan for Q3 2025, a 44.40% increase year-on-year. For the first three quarters of 2025, the revenue reached 1.08257 billion yuan, up 46.22% compared to the same period last year [2] - Domestic SOC chip manufacturer, Rockchip, forecasted a net profit attributable to the parent company between 760 million and 800 million yuan for the first three quarters of 2025, representing a year-on-year growth of 116% to 127%. The net profit growth for Q3 alone is estimated at around 50%, which is lower than the first half of the year due to a shift in customer demand from DDR4 to DDR5 chips [2] Group 2: General Power Machinery Industry - Zongshen Power announced a net profit forecast of 665 million to 782 million yuan for the first three quarters of 2025, reflecting a significant year-on-year increase of 70% to 100%. The growth is attributed to the expansion of general machinery and motorcycle engine businesses, as well as improved earnings from joint ventures [3] - The performance of Longxin General, a similar business, also indicated a net profit growth of over 70% for Q3, suggesting strong overseas demand in the general power machinery sector [3] Group 3: Advanced Manufacturing Industry - The price of lithium hexafluorophosphate surged from 58,300 yuan per ton on September 26 to 71,500 yuan per ton by October 13. This price increase is driven by supply constraints from small enterprises and a surge in demand from the energy storage sector [6] - The increase in lithium hexafluorophosphate prices has led to a cost increase of approximately 0.40-0.59 yuan/kWh for battery cells, with a minor impact on overall system costs but a significant effect on the profitability of electrolyte manufacturers [6] Group 4: Consumer Sector - Morning Glory Bio announced a projected net profit of 278 million to 314 million yuan for the first three quarters of 2025, representing a year-on-year increase of 344.05% to 401.55%. The growth is primarily driven by the recovery in cottonseed product prices and improved oil extraction efficiency, alongside strong performance in the plant extraction business [8] - The plant extraction segment has shown a notable recovery, contributing to both revenue and gross profit growth, thereby supporting the overall performance of the company [8]